Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
25.06. | US FDA approves GSK's Benlysta autoinjector for lupus nephritis | ||
25.06. | GE HealthCare's PET imaging agent gains Alzheimer's label expansion | ||
25.06. | Medera and Novoheart collaborate on mini-heart models for HLHS | ||
25.06. | Alzheimer's R&D resurgence driven by $16.8bn in acquisitions in 2025YTD | ||
25.06. | Revolution Medicines partners Royalty Pharma on $2bn funding | ||
25.06. | FDA approves Sanofi and Regeneron's Dupixent for bullous pemphigoid | ||
24.06. | Pharmaceutical Technology Excellence Awards 2025: i3 Membrane | ||
24.06. | Overcoming technical challenges in gene therapy product fill-finish operations | ||
24.06. | Zambon gains Chinese regulatory authority approval for Fluimucil IV | ||
24.06. | Navamedic signs agreement to acquire dne pharma | ||
24.06. | Hims & Hers shares plummet 35% as Novo Nordisk pulls partnership plug | ||
24.06. | FDA genAI reviews hinge on clarity of dossiers | ||
24.06. | FDA approves AstraZeneca and Daiichi Sankyo's Datroway for NSCLC | ||
23.06. | Bayer's Eylea market grip set to slip as Alvotech biosimilar closes in | ||
23.06. | Harbour BioMed partners Otsuka on new T-cell therapy | ||
23.06. | Bridging the gap: A comprehensive approach to social determinants of health | ||
23.06. | EC approves argenx's efgartigimod alfa for CIDP treatment | ||
23.06. | From discovery to delivery: making therapies reach patients faster | ||
20.06. | Madrigal poised to enter European MASH market after CHMP endorsement | ||
20.06. | London Biotechnology Show 2025: Novo Nordisk harnesses AI/ML to accelerate drug development landscape | ||
20.06. | Podcast: Uses of blockchain in healthcare | ||
20.06. | Novartis' ribociclib approved in Canada for early breast cancer | ||
20.06. | FDA cell and gene therapy director exit increases 'volatility' for sector | ||
20.06. | NSW government invests $13.39m in life-changing therapies | ||
20.06. | DoH - Abu Dhabi and Sanofi link for vaccine development |